The third-generation EGFR inhibitor olmutinib [8,9] (3) was developed by Hanmei Pharmaceutical Company, and is an irreversible inhibitor for the treatment of patients with locally advanced or EGFRT790M-mutant NSCLC (Figure 2) [10]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.